Zusammenfassung
Das Reizdarmsyndrom ist eine häufige gastroenterologische Erkrankung mit vielfältigen
subjektiven Beschwerden. Die Störung der kommensalen Darmflora, die erhöhte mukosale
Permeabilität und die mukosal erhöhte Präsenz verschiedener Zellen und ihrer Chemokine
sind therapeutische Ansatzpunkte. EcL-Extrakt ist der Wirkstoffkomplex eines
bakterien- und eiweißfreien Darmschleimhaut- und Immuntherapeutikums, gewonnen
aus den Stoffwechselprodukten des probiotischen Bakteriums Escherichia coli Stamm
Laves 1931. In zwei multizentrischen Praxisstudien mit 65 und 104 Patienten wurde
die Wirksamkeit und Verträglichkeit dieses Arzneimittels bei Kindern und Erwachsenen
mit Reizdarmsyndrom untersucht. Im Rahmen der vorliegenden Studien am Reizdarmsyndrom
wurden die Erfahrungen am Markt bestätigt, dass EcL-Extrakt ein sicheres und wirksames
Arzneimittel zur Behandlung des Reizdarmsyndroms darstellt. Über eine symptomatische
Wirkung hinausgehend konnte eine anhaltende, kurative Wirkung von EcL-Extrakt
belegt werden. EcL-Extrakt ist gemäß der Beurteilung der behandelnden Ärzte
und Patienten gut bis sehr gut verträglich und bewirkt keine neuen, medikationsbedingten
Beschwerden. EcL-Extrakt stellt deshalb eine wertvolle Therapievariante des Reizdarmsyndroms
dar, welche bezüglich Wirksamkeit und Verträglichkeit anderen Therapien überlegen
ist.
Abstract
Inflammatory bowel disease (IBD) is the most prevalent gastroenterological motility
disorder with diverse subjective discomfort. Dysfunction of the commensal microflora,
increased mucosal permeability, increased levels of immunocompetent cells and
their chemokines are the prevalent therapeutic targets. EcL-digest (extract) is
the cell- and protein-free, pharmaceutically active ingredients composite of a
gut mucosa drug and immunotherapeutic agent prepared from the probiotic commensal
E. coli spec. Laves 1931.
Efficiency and compatibility of this drug was reinvestigated for IBD in children
and adults in two multicenter-trials involving 65 and 104 patients, respectively.
This study confirmed the former investigations, trials and market experiences,
that EcL-digest is a save and compatible drug for the treatment of IBD. Furthermore,
a prolonged and curative success of EcL-digest was confirmed. As pointed out by
therapeutics and patients, EcL-digest is highly compliant in the absence of adverse
effects. Hence, EcL-digest therapy exhibits a valuable therapeutic variant for
IBD, which is superior in compliance and compatibility to the other treatments.
Schlüsselwörter
Reizdarmsyndrom - Colon irritabile - Escherichia coli - E. coli Laves 1931 - LC-Extrakt,
Colibiogen® - Probiotika, klinische Studie - Rome-Kriterien - Darm - Darmschleimhaut
- Mukosa - kommensale Darmflora - Diarrhöe - Obstipation - abdominale Schmerzen -
erhöhte Permeabilität - Mukositis - Kolitis - Gastroenteritis - Entzündung - funktionelle
Darmbeschwerden
Keywords
Irritable bowel syndrome - Escherichia coli - E. coli Laves 1931 - EcL-Extract - Colibiogen®
- probiotics - clinical trial - Rome-criteria - gut - intestinal mucosa - commensal
flora - diarrhoea - constipation - abdominal pain - increased mucosal permeability
- mucositis - colitis - gastroenteritis - inflammation - functional gut discomfort
Literatur
- 01
Barbara G.
Mucosal barrier defects in irritable bowel syndrome. Who left the door open?.
Am J Gastroenterol.
2006;
101
(6)
1295-1298
- 02
Barbara G. et al. .
Mast cell-dependent excitation of visceral-nocieptive sensory neurons in irritable
bowel syndrome.
Gastroenterology.
2007;
132
(1)
26-37
- 03
Brockmann B. et al. .
Modulation of 5-Fluorouracil treatment in advanced gastrointestinal and breast
carcinoma with Colibiogen®.
Onkologie. International Journal for Cancer Research and Treatment.
1994;
17
(S 2)
- 04
Camilleri M. et al. .
Improvement in pain and bowel function in female irritable bowel patients with
alosetron, a 5-HT3 receptor antagonist.
Aliment Pharmacol Ther.
1999;
13
1149-59
- 05
Crowell M D, Wessinger S B.
5-HT and the brain-gut axis: opportunities for pharmacologic intervention.
Expert Opin Investig Drugs.
2007;
16
(6)
761-765
- 06
Drossmann D A, Whitehead W E, Camilleri M.
Irritable bowel syndrome: a technical review for practice guideline development.
Gastroenterol.
1997;
112
2120-2137
- 07
Dunlop S P. et al. .
Abnormal intestinal permeability in subgroups of diarrhea.predominant irritable
bowel syndromes.
Am J Gastroenterol.
2006;
101
(6)
1288-1294
- 08
Freitas M, Cayuela C, Antoine J M, Piller F, Sapin C, Trugnan G.
A heat labile soluble factor from Bacteroides thetaiotaomicron VPI-5482 specifically
increases the galactosylation pattern of HT29-MTX cells.
Cell Microbiol.
2001;
3
289-300
- 09
Frissora C L, Cash B D.
Review article: the role of antibiotics vs. Conventional pharmacotherapy in
treating symptoms of irritable bowel syndrome.
Aliment Pharmacol Ther.
2007;
25
(11)
1271-1281
- 10
Guilarte M. et al. .
Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia
in the jejunum.
Gut.
2007;
56
(2)
203-209
- 11
Hämling J, Bang C J, Tarpila S, Stewart W, Rueegg P C.
Titration regimen indicates partial 5-HT agonist HTF 919 improves symptoms of
constipation predominant irritable bowel syndrome.
Digestion.
1998;
59
735
- 12
Hartwich R, Christians U, Thomsen A.
Pilotstudie: Symptomatische Besserung der strahleninduzierten Colitis durch
Peptidextrakt aus E. coli.
Klinikarzt.
1998;
6
(27)
48-52
- 13
Hotz J, Enck P O, Goebell H, Heymann-Mönnikes I, Holtmann G, Layer P.
Konsensusbericht: Reizdarmsyndrom - Definition, Diagnosesicherung, Pathophysiologie
und Therapiemöglichkeiten.
Z Gastroenterol.
1999;
37
685-700
- 14
Jones R, Latinovic R, Charlton J, Gulliford M.
Physical and psychological co-morbidity in irritable bowel synedrome: A matched
cohort study using the General Practice Research Database.
Aliment Pharmacol Ther.
2006;
24
(5)
879-886
- 15
Kellow J E, Delvaux M, Azpiroz F, Camilleri M, Quigley E M M, Thompson D G.
Principles of applied neurogastroenterology: physiology/motility-sensation.
Gut.
1999;
45
II17-II24
- 16
Kirsch R, Riddell R H.
Histopathological alterations in irritable bowel syndrome.
Mod Pathol.
2006;
19
(12)
1638-1645
- 17
Kline R M, Kline J, Palma J di, Barbero G J.
Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable
bowel syndrome in children.
J Pediatr.
2001;
138
125-8
- 18
Koebnick C. et al. .
Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal
symptoms in patients with chronic constipation.
Can J Gastroenterol.
2003;
17
(11)
655-659
- 19 Konrad A, Maehler M, Flogerzi B, Egger B, Kalousek M B, Seibold F. Prevention of
murine colitis by feeding a soluble fraction of E. coli.: Digestive Disease
Week. Atlanta; 2001
- 20
Kruis W, Weinzierl M, Schüssler P, Holl J.
Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in
patients with the irritable bowel syndrome.
Digestion.
1986;
34
196-201
- 21
La J H, Kim T W, Sung T S, Kim H J, Kim J Y, Yang I S.
Role of mucosal mast cells in visceral hypersensitivity in a rat model of irritable
bowel syndrome.
J Vet Sci.
2004;
5
(4)
319-324
- 22
Langaker K J, Morris D, Pruitt R O M, Stewart W, Rueegg P C.
The partial 5-HT (HTF919) improves symtoms in constipation-predominant irritable
bowel syndrome.
Digestion.
1998;
59
20
- 23
Liu J H, Chen G H, Yeh H Z, Huang C K, Poon S K.
Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome:
a prospective, randomized trial.
J Gastroenterol.
1997;
32
765-768
- 24
Mawe G M, Coates M D, Moses P L.
Review article: intestinal serotonin signalling in irritable bowel syndrome.
Aliment Pharmacol Ther.
2006;
23
(8)
1067-1076
- 25
Maxwell P R, Rink E, Kumar D, Mendall M A.
Antibiotics increase functional abdominal symptoms.
Am J Gastroenterol.
2002;
97
104-108
- 26
OŽMahony L. et al. .
Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses
and relationship to cytokine profiles.
Gastroenterology.
2005;
128
541-551
- 27
Mittelstaedt A, Sonnenschein B, Sporrer M.
Morbus Crohn: Besserung durch ein Zucker-Peptid-Gemisch.
Ärztliche Praxis.
1983;
28
777-781
- 28
Müller E, Sonnenschein B, Petzoldt K.
Tierexperimentelle Untersuchungen über die Beeinflussung der nichterregerspezifischen
Abwehr durch Stoffwechselprodukte von E. coli.
Zbl Vet Med.
1985;
32
744-750
- 29
Quigley E M.
Bacterial flora in irritable bowel syndrome: Role in pathophysiology, implications
for management.
J Dig Dis.
2007;
8
(7)
2-7
- 30
Quigley E M, Flourie B.
Probiotics and irritable bowel syndrome: a rationale for their use and an assessment
of the evidence to date.
Neurogastroenterol Motil.
2007;
19
(3)
166-172
- 31 Rasquin-Weber A. Childhood functional gastrointestinal disorders. Gut 1999 45
II60-II68 [Record as supplied by publisher]: II60-II68
- 32
Riordan S M, Kim R.
Bacterial overgrowth as a cause of irritable bowel syndrome.
Curr Opin Gastroenterol.
2006;
22
(6)
669-673
- 33
Schultze W, Brockmann B, Loppnow H, Preiß H, Thomsen A, Possinger K.
Effect of the E. coli extract Colibiogen on the growth pattern of hemopoietic
cells in vitro. 21. Deutscher Krebskongress. Hamburg 1994.
Journal of Cancer Research and Clinical Oncology.
1994;
120
- 34
Sheil B. et al. .
Is the mucosal route of administration essential for probiotic function? Subcutaneous
administration is associated with attenuation of murine colitis and arthritis.
Gut.
2004;
53
694-700
- 35
Spanhaak S. et al. .
The effect of milk fermented by Lactobacillus casei Shirota on the intestinal
microflora and immune parameters in humans.
Eur J Clin Nutr.
1998;
52
899-907
- 36
Spiller R C.
Role of infection in irritable bowel syndrome.
J Gastroenterol.
2007;
42
(17)
41-47
- 37
Thompson W G, Longstreth G F, Drossman D A, Heaton K W, Irvine E J, Müller-Lissner S A.
Functional bowel disorders and functional abdominal pain.
Gut.
1999;
45
II43-II47
- 38
Thomsen A.
Colibiogen modulates cytokine production in human mononuclear cells (MNC) in
vitro. 21. deutscher Krebskongress Hamburg 1994.
Journal of Cancer Research and Clinical Oncology.
1994;
120
- 39
Unger C. et al. .
Arzneimittel-Forschung.
Drug Research.
2001;
51
(I)
332-338
01 Colibiogen® Kinder, 1 ml enthält: zellfreie Lösung aus 1,3 × 108 lysierten E. coli Stamm Laves 1931, Laves-Arzneimittel GmbH.
02 Colibiogen® oral, 1 ml enthält: zellfreie Lösung aus 2,3 × 108 lysierten E. coli Stamm Laves 1931, Laves-Arzneimittel GmbH.
Korrespondenzadresse
Dr. Kirsten Klug
Laves Arzneimittel GmbH
Barbarastr. 14
30952 Ronneburg
Phone: 0511/438740
Fax: 0511/4387444
Email: fachservice@laves-pharma.de
URL: http://www.laves-pharma.de
